CTLA4 and melanoma: The analysis of the effect of combining anti-CTLA-4 and anti-PD-1 antibodies with guadecitabine presented here anticipates the expected results of an ongoing clinical phase-II trial using this combination in melanoma and lung cancer patients who are resistant to anti-PD-1/-PD-L1 therapy (NCT04250246) [30].